Drugs that contain Linagliptin; Metformin Hydrochloride
1. Jentadueto patents expiration
JENTADUETO's oppositions filed in EPO
JENTADUETO Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 13 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(6 years ago) | |
| US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 6 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 7 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
| US10973827 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
|
US10973827 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
|
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-146) | Jul 30, 2017 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...
Dosage: TABLET;ORAL
How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage
JENTADUETO family patents
2. Jentadueto Xr patents expiration
JENTADUETO XR's oppositions filed in EPO
JENTADUETO XR Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 13 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6340475 | BOEHRINGER INGELHEIM | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6635280 | BOEHRINGER INGELHEIM | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6303661 | BOEHRINGER INGELHEIM | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(6 years ago) | |
| US7459428 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | BOEHRINGER INGELHEIM | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6488962 | BOEHRINGER INGELHEIM | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
Jun, 2020
(3 years ago) | |
| US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
| US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(8 months ago) | |
|
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(1 year, 6 months from now) | |
| US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(1 year, 7 months from now) | |
|
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
|
US9173859 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
Nov, 2027
(3 years from now) | |
|
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(3 years from now) | |
| US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
| US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(4 years from now) | |
|
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
|
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(5 years from now) | |
| US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
|
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(6 years from now) | |
| US9555001 | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Mar, 2033
(8 years from now) | |
|
US9555001 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition and uses thereof |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dip...
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage
JENTADUETO XR family patents